BRCA1 and sarcoma: ATRis have been shown to sensitize BRCA1/2-deficient and wild-type ovarian and breast cancer cell lines55–57 and sarcoma cells58 to PARPis, leading to a number of clinical trials in patients with solid tumors (i.e., NCT03462342, NCT03682289, NCT02723864).